{"id":"daratumumab-ixazomib-dexamethasone","safety":{"commonSideEffects":[{"rate":"40%","effect":"Fatigue"},{"rate":"30%","effect":"Nausea"},{"rate":"20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1743007","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Daratumumab binds to CD38 on the surface of multiple myeloma cells, marking them for destruction by the immune system.","oneSentence":"Daratumumab is a monoclonal antibody that targets CD38.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:09.200Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT03283917","phase":"PHASE1","title":"Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-07","conditions":"Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis","enrollment":21},{"nctId":"NCT05675319","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2023-03-03","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT04009109","phase":"PHASE2","title":"Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2020-10-21","conditions":"Myeloma, Multiple","enrollment":79},{"nctId":"NCT04068597","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","status":"RECRUITING","sponsor":"CellCentric Ltd.","startDate":"2019-08-09","conditions":"Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma","enrollment":250},{"nctId":"NCT03763162","phase":"PHASE2","title":"Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-17","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":40},{"nctId":"NCT03590652","phase":"PHASE2","title":"Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2018-10-17","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":23},{"nctId":"NCT01415882","phase":"PHASE2","title":"Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-31","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":165},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401},{"nctId":"NCT04790474","phase":"PHASE2","title":"Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2021-03-25","conditions":"Multiple Myeloma in Relapse, Refractory Multiple Myeloma","enrollment":61},{"nctId":"NCT04052880","phase":"PHASE2","title":"Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Larysa Sanchez","startDate":"2019-10-24","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":17},{"nctId":"NCT05451771","phase":"PHASE1, PHASE2","title":"Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis","status":"RECRUITING","sponsor":"Rajshekhar Chakraborty, MD","startDate":"2022-10-26","conditions":"AL Amyloidosis","enrollment":53},{"nctId":"NCT03012880","phase":"PHASE2","title":"Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-04-20","conditions":"Plasma Cell Myeloma","enrollment":80},{"nctId":"NCT03732703","phase":"PHASE1, PHASE2","title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","status":"COMPLETED","sponsor":"Multiple Myeloma Research Consortium","startDate":"2019-04-01","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":103},{"nctId":"NCT03439293","phase":"PHASE2","title":"A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-03-13","conditions":"Multiple Myeloma","enrollment":61},{"nctId":"NCT03942224","phase":"PHASE2","title":"Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-07-03","conditions":"Plasma Cell Myeloma","enrollment":49},{"nctId":"NCT03651128","phase":"PHASE3","title":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":381},{"nctId":"NCT03669445","phase":"PHASE2","title":"Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma","status":"UNKNOWN","sponsor":"University Hospital, Toulouse","startDate":"2018-12-31","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT03757221","phase":"PHASE2","title":"Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2019-02-07","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT03746652","phase":"PHASE2","title":"Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Hellenic Society of Hematology","startDate":"2018-12","conditions":"Multiple Myeloma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Daratumumab, Ixazomib, Dexamethasone","genericName":"Daratumumab, Ixazomib, Dexamethasone","companyName":"Hellenic Society of Hematology","companyId":"hellenic-society-of-hematology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daratumumab is a monoclonal antibody that targets CD38. Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}